Semi-Annual Surveillance Report
Jan. 1 – June 30, 2026

Semi-annual summary of the epidemiology of the confirmed cases of TB disease reported to the Minnesota Department of Health from Jan. 1 - June 30, 2026.

Updated 7/2026

NOTE: Percentages may not total 100% due to rounding.

• Download PDF version formatted for print:
  Tuberculosis Semi-Annual Surveillance Report, Jan. 1-June 30, 2026 (PDF)
• Download PDF version (with previous year's data for comparison):
  Tuberculosis Semi-Annual Report with Data Comparison, Jan. 1-June 30, 2026 (PDF)

On this page:
Table 1. Number of Cases of Tuberculosis by Location of Residence, Minnesota
Table 2. Number of Cases of Tuberculosis by Race/Ethnicity, Minnesota
Table 3. Number of Cases of Tuberculosis by Age, Minnesota
Table 4. Number of Cases of Tuberculosis by Risk Category, Minnesota
Table 5. Number of Cases of Drug-Resistant Tuberculosis, Minnesota
Table 6. Number of Cases of Tuberculosis by Site of Disease, Minnesota
Table 7. Number of Cases of Tuberculosis by Method of Case Identification, Minnesota

YTD: Year to date

Table 1. Number of Cases of Tuberculosis by Location of Residence, Minnesota

*Anoka, Carver, Dakota, Scott, and Washington counties

Table 2. Number of Cases of Tuberculosis by Race/Ethnicity, Minnesota

Table 3. Number of Cases of Tuberculosis by Age, Minnesota

Table 4. Number of Cases of Tuberculosis by Risk Category, Minnesota*

*Risk categories are not mutually exclusive
**Excess alcohol use or injection and/or non-injection drug use (not prescribed by health care provider or misuse of prescribed drugs)
+Silicosis, diabetes, prolonged corticosteroid therapy or other immunosuppressive therapy, hematologic/reticuloendothelial disease, end stage renal disease, substantial weight loss (not TB-related) or undernutrition

Table 5. Number of Cases of Drug-Resistant Tuberculosis, Minnesota

*Culture-confirmed cases with growth-based drug susceptibility results available
**Resistant to at least one first-line anti-TB drug [i.e., isoniazid (INH), rifampin, pyrazinamide (PZA), or ethambutol]
+ May also have resistance to other drugs
# Primary multi-drug resistant TB (i.e., resistance to at least INH and rifampin from initial isolates of patients with no prior history of TB)

Table 6. Number of Cases of Tuberculosis by Site of Disease, Minnesota

*TB cases with both pulmonary and extrapulmonary sites of disease

Table 7. Number of Cases of Tuberculosis by Method of Case Identification, Minnesota

*Infectious, active TB disease ruled out overseas
**e.g., occupational screening, other targeted TB testing, etc.